Assessing the impact of safety monitoring on the efficacy analysis in large Phase III group sequential trials with non-trivial safety event rate.

about

Assessing the impact of safety monitoring on the efficacy analysis in large Phase III group sequential trials with non-trivial safety event rate.

Item

http://www.wikidata.org/entity/Q36322674

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh

2015年學術文章

@zh-hant

name

Assessing the impact of safety ...... non-trivial safety event rate.

@ast

Assessing the impact of safety ...... non-trivial safety event rate.

@en

type

Item

label

Assessing the impact of safety ...... non-trivial safety event rate.

@ast

Assessing the impact of safety ...... non-trivial safety event rate.

@en

prefLabel

Assessing the impact of safety ...... non-trivial safety event rate.

@ast

Assessing the impact of safety ...... non-trivial safety event rate.

@en

P1476

Assessing the impact of safety ...... non-trivial safety event rate.

@en

P2093

Stacia M DeSantis

http://www.w3.org/2001/XMLSchema#string

Wenle Zhao

http://www.w3.org/2001/XMLSchema#string

Yanqiu Weng

http://www.w3.org/2001/XMLSchema#string

Yuko Y Palesch

http://www.w3.org/2001/XMLSchema#string

P2860

Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group

The albumin in acute stroke (ALIAS) multicenter clinical trial: safety analysis of part 1 and rationale and design of part 2.

On being the statistician on a Data and Safety Monitoring Board.

Monitoring the randomized trials of the Women's Health Initiative: the experience of the Data and Safety Monitoring Board.

Testing a primary and a secondary endpoint in a group sequential design.

Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.

Impact of safety monitoring on error probabilities of binary efficacy outcome analyses in large phase III group sequential trials.

The conscientious judgement of a DSMB--statistical stopping rules re-examined.

Adaptive extensions of a two-stage group sequential procedure for testing primary and secondary endpoints (I): unknown correlation between the endpoints.

Design and analysis of group sequential clinical trials with multiple primary endpoints.

P304

672-685

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/10543406.2015.1052473

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-05-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26010228

http://www.w3.org/2001/XMLSchema#string

P921

phase III clinical trial

P932

4661138

http://www.w3.org/2001/XMLSchema#string